School of Medicine
Showing 501-510 of 739 Results
-
Ed Petrossian
Clinical Professor, Cardiothoracic Surgery
Current Research and Scholarly InterestsDr. Petrossian has expertise in complex pediatric and congenital cardiovascular surgical repairs. He has published several journal articles and book chapters with an emphasis on the extracardiac conduit Fontan operation.
-
Jena Pizula, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Pizula is a quadruple board-certified, fellowship-trained cardiologist with Stanford Health Care Cardiovascular Health. She is also a clinical assistant professor in the Department of Medicine, Division of Cardiovascular Medicine at Stanford University School of Medicine. She completed a fellowship in cardiovascular medicine at the University of Southern California (USC) Keck School of Medicine.
Dr. Pizula specializes in cardio-obstetrics. She works with women before, during, and after pregnancy to determine their risk of heart-related pregnancy complications and improve their cardiovascular health. She has experience managing complex cardiovascular conditions, including congenital heart disease, arrhythmias, coronary artery disease, valvular disease, and cardiomyopathy. Dr. Pizula develops a customized care plan for each patient she treats. As a leader in cardio-obstetrics, she’s at the forefront of the latest advances in women’s cardiovascular care.
Her research interests include the intersection of cardiovascular disease and pregnancy. She focuses on how pre-existing conditions like congenital heart disease, cardiomyopathy, or hypertension affect pregnancy. She has also explored how physiological changes during pregnancy affect existing heart disease and long-term cardiovascular risk. She uses her unique dual background in internal medicine and pediatrics to study how adult manifestations of cardiovascular disease impact pregnancy outcomes.
Dr. Pizula is active in teaching medical students, internal medicine and obstetrical residents, and cardiology fellows. She teaches them strategies to improve how they assess and manage risk and deliver postpartum care to people with high-risk cardiac pregnancies. Dr. Pizula is the director of the Finishing School for Future Cardiologists for the California chapter of the American College of Cardiology, which offers leadership development to cardiology fellows.
Dr. Pizula’s research has been published in the Journal of the American Heart Association, Journal of the American College of Cardiology, The Journal of Heart and Lung Transplantation, Journal of General Internal Medicine, and Pediatrics. She has authored three book chapters on cardio-obstetrics and global emergency medicine.
Dr. Pizula has presented her research at conferences in the United States and internationally. As an expert in cardiovascular disease and pregnancy, she is frequently invited to speak to cardiologists, obstetricians, and anesthesiologists at the International Congress on Cardiac Problems in Pregnancy. She currently serves as a reviewer for the European Journal of Heart Failure and Heart Failure Reviews.
Dr. Pizula is a member of the American College of Cardiology, Stanford Medicine Cardiovascular Institute, and Stanford Medicine Maternal & Child Health Research Institute. -
Ada Poon
Associate Professor of Electrical Engineering
Current Research and Scholarly InterestsOur research focuses on providing theoretical foundations and engineering platforms for realizing electronics that seamlessly integrate with the body. Such systems will allow precise recording or modulation of physiological activity, for advancing basic scientific discovery and for restoring or augmenting biological functions for clinical applications.
-
Richard Popp
Professor of Medicine (Cardiovascular Medicine), Emeritus
Current Research and Scholarly InterestsAcademic-Industrial relations; Ethics of invention.
-
Matthew Porteus
Sutardja Chuk Professor of Definitive and Curative Medicine
BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.
-
Guillem Pratx
Associate Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.
-
James Priest
Adjunct Clinical Assistant Professor, Pediatrics - Cardiology
Current Research and Scholarly InterestsThe Priest lab seeks a better understanding of the genetics and pathogenesis of congenital heart disease using translational genomics, big-data, and vertebrate models of cardiac development.
-
Lei (Stanley) Qi
Associate Professor of Bioengineering
BioDr. Lei (Stanley) Qi (publishes as Lei S. Qi) is an Associate Professor in the Department of Bioengineering at Stanford University, an Institute Scholar at Sarafan ChEM-H, and a Chan Zuckerberg Biohub Investigator. Trained in physics and mathematics (Tsinghua University) and bioengineering (UC Berkeley), he was a Systems Biology Fellow at UCSF before joining the Stanford faculty in 2014.
Qi is a pioneer in CRISPR technology and genome engineering. His lab created the first nuclease-deactivated Cas9 (dCas9) for targeted gene regulation, establishing CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa). Since then, his group has expanded CRISPR from an editing tool into a platform for programmable control of dynamic and spatial cell state, integrating scalable perturbation, live-cell and super-resolution imaging, and computation-guided design. This work has produced technologies for multiplexed transcriptome regulation, programmable 3D genome organization, spatial RNA logistics control, and real-time visualization of chromatin and transcriptional events in living cells.
A distinctive focus of the Qi lab is closed-loop biology, combining perturbation with high-content measurements to infer mechanisms and iteratively refine control strategies. The lab develops platforms spanning multiplexed transcriptional and epigenetic control, spatial genome–transcriptome organization, and quantitative live-cell imaging of chromatin and transcriptional dynamics. A compact nuclease-dead CRISPR epigenetic editor from this technology lineage has advanced to first-in-human clinical testing for facioscapulohumeral muscular dystrophy (FSHD; NCT06907875), underscoring the translational potential of principle-driven control systems.
Beyond single-cell control, Qi’s lab is building a framework for synthetic cell–cell communication, with particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors. By integrating experimental bioengineering with computation and machine learning, the lab aims to identify generalizable rules linking molecular programs to systems-level physiology and disease trajectories and to translate those rules into next-generation therapeutic cells.
